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Chronic kidney disease (CKD) and NAFLD: Time for awareness
and screening
NAFLD was deﬁned by liver histology in 13 studies (2205 partic-
ipants). NAFLD was associated with an increased prevalence (OR
2.12, 95% CI 1.69–2.66) and incidence (HR 1.79, 95% CI 1.65–1.95)
of CKD. In non-cirrhotic biopsy-proven NAFLD patients, NASH
was associated with a higher prevalence (OR 2.53, 95% CI 1.58–
4.05) and incidence (HR 2.12, 95% CI 1.42–3.17) of CKD than
simple steatosis. Similarly, NAFLD with advanced ﬁbrosis was
associated with a higher CKD prevalence (OR 5.20, 95% CI 3.14–
8.61) and incidence (HR 3.29, 95% CI 2.30–4.71) than NAFLD with
milder ﬁbrosis stages. Remarkably, the severity of NAFLD was
positively associated with CKD stages, with NASH and advanced
ﬁbrosis conferring a greater risk of developing stage 5 CKD (renal
failure) than simple steatosis and milder ﬁbrosis stages,
respectively.
In all analyses, the magnitude and direction of effects
remained unaffected by diabetes status (present vs. absent) and
after adjustment for other traditional risk factors for CKD
(including age, obesity, metabolic syndrome components,
smoking, hypertension, race).
The prevalence of CKD, as well as NAFLD, is continuously
rising in concert with the epidemic of its risk factors, including
diabetes, obesity and metabolic syndrome. Although early recog-
nition and treatment of CKD have been shown to reduce the stag-
gering cost of CKD and related hospitalizations [6], CKD often
goes unrecognized, and in the Third National Health and Nutri-
tion Survey (NHANES III), among all individuals with moderately
decreased GFR (stage 3 CKD), the awareness approached 8.2% [7].
Since current therapeutic options to reverse CKD in liver
transplant recipients are limited, the ﬁndings discussed above
emphasize the need for practicing hepatologists to recognize
early CKD in chronic liver disease patients and in NAFLD in par-
ticular, to optimize the management of these patients by delaying
renal disease progression. From a therapeutical stand-point,
promising preliminary evidence from randomized trials suggest
several available pharmacological classes provide incremental
beneﬁts on renal disease progression over others, with statins
[8] and angiotensin receptor blockers slowing renal function
JOURNAL OF HEPATOLOGYTo the Editor:
We read with interest the article by Allen et al. reporting
on the high prevalence and associated mortality of chronic
kidney disease (CKD), in patients who had undergone liver
transplantation [1].
We believe a thorough interpretation of these ﬁndings, which
are consistent with recent liver transplant literature, should take
into account the evolving aetiological spectrum of liver disease in
both patients candidate for liver transplantation as well as in
those with milder stage disease [2]: in either case, non-alcoholic
steatohepatitis (NASH) is as an emerging risk factor for renal dys-
function, as compared with other aetiologies of cirrhosis. An anal-
ysis of the United Network Organ Sharing (UNOS) database,
during the years 2002–2011, shows NASH-related cirrhosis as
an increasing indication for simultaneous liver-kidney transplan-
tation (SLKT) [3]. A concerning observation was the reduced
5-year liver graft, kidney graft, and patient survival in NASH
patients in comparison to transplantation for other causes of cir-
rhosis (HR of 2.50 (95% CI 1.10–5.80), 2.30 (1.10–5.10), and 2.20
(1.02–5.79) respectively), for loss of liver transplant, loss of kid-
ney graft, and death. These ﬁndings are consistent with European
data suggesting NASH as a risk factor for severe renal impairment
after liver transplantation; Houlihan et al. [4] reported more rapid
loss of renal function in patients receiving a liver transplant for
NASH-related cirrhosis in comparison to other aetiologies of cir-
rhosis (OR for incident CKD in NASH vs. controls of 2.43 (95% CI
1.05–5.63)) 2 years after liver transplantation, independent of
BMI, diabetes, hypertension, hepatocellular carcinoma, and
tacrolimus levels. Remarkably, 35% of patients transplanted for
NASH-related cirrhosis progressed to stage 3b-4 CKD within
2 years after liver transplantation, compared to 10% of patients
transplanted for other aetiologies of cirrhosis.
The evidence connecting NAFLD to CKD is also emerging in the
general population: we recently subjected studies, assessing the
association of NAFLD with CKD, to meta-analysis [5], which
included 33 studies (63,902 participants, 16 population-based
and 17 hospital-based, 20 cross-sectional and 13 longitudinal).
For 20 studies, individual participant data were obtained and decline and ameliorating proteinuria [9], in addition to the
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amelioration of markers of steatosis and liver histology in
non-cirrhotic NASH [10]. Future trials should also evaluate the
impact of experimental drugs on renal function, which is
currently reported in less than 10% of available randomized tri-
als in NASH.
Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.
References
[1] Allen AM, Kim WR, Therneau TM, Larson JJ, Heimbach JK, Rule AD. Chronic
kidney disease and associated mortality after liver transplantation–a time-
dependent analysis using measured glomerular ﬁltration rate. J Hepatol
2014;61:286–292.
[2] Singal AK, Guturu P, Hmoud B, Kuo YF, Salameh H, Wiesner RH. Evolving
frequency and outcomes of liver transplantation based on etiology of liver
disease. Transplantation 2013;95:755–760.
[3] Singal AK, Salameh H, Kuo YF, Wiesner RH. Evolving frequency and outcomes
of simultaneous liver kidney transplants based on liver disease etiology.
Transplantation 2014;98:216–221.
[4] Houlihan DD, Armstrong MJ, Davidov Y, Hodson J, Nightingale P, Rowe IA,
et al. Renal function in patients undergoing transplantation for nonalcoholic
steatohepatitis cirrhosis: time to reconsider immunosuppression regimens?
Liver Transpl 2011;17:1292–1298.
[5] Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M,
et al. Association of non-alcoholic fatty liver disease with chronic kidney
disease: a systematic review and meta-analysis. PLoS Med 2014;11:
e1001680. http://dx.doi.org/10.1371/journal.pmed.1001680.
[6] Black C, Sharma P, Scotland G, McCullough K, McGurn D, et al. Early referral
strategies for management of people with markers of renal disease: a
systematic review of the evidence of clinical effectiveness, cost-effectiveness
and economic analysis. Health Technol Assess 2010;14:1–184.
[7] Coresh J, Byrd-Holt D, Astor BC, Briggs JP, Eggers PW, et al. Chronic kidney
disease awareness, prevalence, and trends among US adults, 1999 to 2000. J
Am Soc Nephrol 2005;16:180–188.
[8] Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, et al.
Safety and efﬁcacy of long-term statin treatment for cardiovascular events in
patients with coronary heart disease and abnormal liver tests in the Greek
Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a
post-hoc analysis. Lancet 2010;376:1916–1922.
[9] Hirata T, Tomita K, Kawai T, Yokoyama H, Shimada A, Kikuchi M, et al. Effect
of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease:
Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY). Int J
Endocrinol 2013;2013. Article ID: 587140.
[10] Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on
liver disease, glucose metabolism and cardiovascular risk in non-alcoholic
fatty liver disease (NAFLD): a systematic review and meta-analysis of
randomised trials. Diabetologia 2012;55:885–904.
Giovanni Musso⇑
Gradenigo Hospital, University of Turin, Turin, Italy⇑Corresponding author.
E-mail address: giovanni_musso@yahoo.it
James H. Tabibian
Michael Charlton
Division of Gastroenterology and Hepatology Mayo Clinic,
Rochester, MN, United States
Reply to: ‘‘Chronic kidney disease (CKD) and NAFLD: Time
for awareness and screening’’
To the Editor:
We appreciate the comments of Musso et al. related to our
manuscript ‘‘Chronic kidney disease and associated mortality
after liver transplantation - a time-dependent analysis using
measured glomerular ﬁltration rate’’ [1]. The authors call
attention to the accumulating evidence of non-alcoholic fatty
liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
as a risk factor for chronic kidney disease (CKD). As NASH cirrho-
sis is emerging as the most common cause of liver transplanta-
tion (LT) [2], the incidence of subsequent CKD may increase.
Whether the changing trends in the etiology of end-stage liver
disease requiring transplantation will impact the risk of CKD post
LT remains to be determined. The anticipated decline of hepatitis
C as a main cause of end-stage liver disease will reduce the prev-
alence of well-deﬁned HCV-associated kidney diseases, such as
cryoglobulinemia and membranoproliferative glomerulopathy
[3]. On the other hand, the increasing prevalence of obesity and
NASH is likely to offset this effect. A growing number of observa-
tions have linked NASH to the development of CKD [4]. While the
exact mechanism of this association is unclear, both share
common cardiometabolic risk factors and the ultimate clinical
consequence of increased risk for cardiovascular morbidity and
mortality.
Efforts to minimize the comorbidity burden associated with
NAFLD may consequently decrease the risk of developing CKD.
Once CKD develops, we agree that statins and angiotensin recep-
tor blockers are helpful in select patients [5]. Unfortunately, more
effective treatments for preventing CKD progression are still
needed. Indeed, a GFR decline into stage 3 CKD (moderately
decreased GFR) is the expected consequence of normal aging
[6] and the American College of Physicians does not recommend
routine screening for moderately decreased GFR in the absence of
risk factors [5]. However, liver transplantation is an unequivocal
risk factor and monitoring for CKD is warranted.
The evolving epidemiology of end-stage liver disease presents
new challenges for the transplant community. Optimization of
long termoutcomesof liver transplant recipientsmaybe improved
with vigilant management of pre and posttransplant metabolic
syndrome and careful adjustment of the immunosuppression reg-
imen. In order to improve the medical care in this population, we
fully agree that renal function should be an investigated endpoint
for randomized trials of novel treatments for NASH.
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